Evidence map›Paper›PMID 40075637›Full record

ReviewCancers2025

From Embryogenesis to Senescence: The Role of Mammary Gland Physiology in Breast Cancer Risk.

Jaida C Lue, Derek C Radisky

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Ageing, immune fitness and cancer.Nature reviews. Cancer · 2025
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jaida C LueGraduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL 32224, USA.
Derek C RadiskyDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-1962-8784

Funding

Predicting Breast Cancer Risk after Benign Percutaneous BiopsyR01CA229811 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, SHERMAN, MARK E · 2018 to 2022
$3.5M
Involution-based biomarkers of breast cancer riskR01CA237602 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, RADISKY, DEREK C · 2020 to 2024
$2.8M
NCI NIH HHS R01 CA229811NCI NIH HHS R01 CA237602NIH HHS 1R01CA237602-05A1
6 · The paper itself

Abstract

The mammary gland undergoes significant changes throughout a woman's life; from embryonic development to transformations after breastfeeding and during aging. These processes, while essential for normal breast physiology, can increase breast cancer risk when disrupted. This review explores three critical stages: embryonic development; postlactational involution; and age-related lobular involution (ARLI). We highlight key signaling pathways-Wnt, FGF, SHH, Notch, EGFR, and BMP-that guide embryonic development and discuss how their dysregulation can contribute to abnormal growth. For postlactational involution, we examine the two-phase process of cell death and tissue remodeling, showing how disruptions during this period, particularly postpartum, may foster a tumor-promoting environment. We also delve into ARLI and the role of cellular senescence in the aging mammary gland, focusing on the senescence-associated secretory phenotype (SASP) and its impact on inflammation and tissue remodeling. Understanding these processes provides new opportunities for breast cancer prevention and treatment strategies.

Indexed as

age-related lobular involution (ARLI)breast cancer riskcellular senescenceembryonic developmentextracellular matrix (ECM)immune modulationmammary gland developmentpostlactational involutionpostpartum breast cancer (PPBC)senescence-associated secretory phenotype (SASP)tumor microenvironment (TME)

Identifiers

PMID40075637
PMCPMC11898936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.